- Briefly describe a specific question, or set of related questions, about a health care test or treatment that this program should consider.
-
What are the benefits and harms of digoxin in the treatment of atrial fibrillation and/or heart failure in older adults? Are the benefits and harms dose dependent, i.e., do they differ for doses less than or equal to 0.125 mg per day compared to 125 mg per day?
- Describe why this topic is important.
-
Regarding digoxin, the pendulum has swung back and forth in the literature. Currently digoxin is listed as avoid as first-line therapy for both conditions in the 2015 AGS Beers Criteria and clinical practice guidelines.
- How will an answer to your research question be used or help inform decisions for you or your group?
-
It will help the AGS Beers Criteria panel decide shape its recommendation for both of these criterion in the 2018 AGS Beers Criteria, particularly if the potential for harm is substantially greater than the expected benefits in a subgroup of older adults, e.g., residents of long term care, ambulatory community-dwelling elderly.
- Other Information About You: (optional)
-
- Please choose a description that best describes your role or perspective: (you may select more than one category if appropriate)
- The American Geriatrics Society (AGS) is a not-for-profit organization of nearly 6,000 health professionals devoted to improving the health, independence and quality of life of all older people.
- If you are you making a suggestion on behalf of an organization, please state the name of the organization
- American Geriatrics Society
- Please tell us how you heard about the Effective Health Care Program
- Through our colleagues at AHRQ, specifically Christine Chang
